HHealthcare Read More How Much Upside Is Left in JNJ Stock?August 28, 2026 While the market fixates on the STELARA patent cliff, the rest of the story is being missed. That…
HHealthcare Read More Can Cost Cuts And 2030 Targets Really Save Pfizer Stock?August 28, 2026 The company now leads with a cost-savings total and a growth rate that does not begin until the…
HHealthcare Read More Can Eli Lilly Stock Keep Surging As Drug Prices Fall?August 27, 2026 The past year’s gain was bought with volume and access, and management has already said net price goes…
HHealthcare Read More Eli Lilly Found a New Gear. You Paid For It.August 26, 2026 Beyond strong drugs, the stock’s ascent was powered by its notable profitability. You watched Eli Lilly (LLY) climb…
HHealthcare Read More Pfizer Stock Is A Race Between New Drugs And Old PatentsAugust 21, 2026 The medicines Pfizer has launched and acquired are arriving at close to the scale of the revenue its…
HHealthcare Read More Why Isn’t Eli Lilly Stock Trading At The Top Of Its Peer Group?August 18, 2026 The market seems to have its pharma giants ranked in a peculiar order, leaving one of the group’s…
HHealthcare Read More Everyone Is Watching Eli Lilly Stock’s New Drugs. Here Is the Metric That VanishedJune 18, 2026 Management once made manufacturing its top priority; now that the topic has gone quiet, it reveals just how…
HHealthcare Read More The Catch Hiding In Eli Lilly Stock’s Growth StoryJune 14, 2026 Eli Lilly’s obesity drug franchise is a juggernaut, but a surprisingly large share of its success relies on…
MMedication Read More A new wave of weight-loss therapies aims to be better than today’s GLP-1sJune 12, 2026 Last Updated: June 7, 2026 at 10:18 a.m. ETFirst Published: June 6, 2026 at 2:53 p.m. ET One of the…
HHealthcare Read More Pfizer, YaoPharma sign $150M GLP-1 obesity drug collaborationDecember 9, 2025 Key Terms phase 1 medical Phase 1 is the first stage of testing…